keyword
MENU ▼
Read by QxMD icon Read
search

Iron hemodialysis

keyword
https://www.readbyqxmd.com/read/28717516/costs-associated-with-intravenous-darbepoetin-versus-epoetin-therapy-in-hemodialysis-patients-a-randomized-controlled-trial
#1
Andrea L Woodland, Sean W Murphy, Bryan M Curtis, Brendan J Barrett
BACKGROUND: Anemia of chronic kidney disease is associated with adverse outcomes and a reduced quality of life. Erythropoiesis-stimulating agents (ESAs) have improved anemia management, and 2 agents are available in Canada, epoetin alfa (EPO) and darbepoetin alfa (DA). EPO and DA are considered equally effective in achieving target hemoglobin (Hb), but it is not clear whether there is a cost difference. There have been few head-to-head comparisons; most published studies are observational switch studies...
2017: Canadian Journal of Kidney Health and Disease
https://www.readbyqxmd.com/read/28704813/serum-ferritin-variations-and-mortality-in-incident-hemodialysis-patients
#2
Taehee Kim, Elani Streja, Melissa Soohoo, Connie M Rhee, Rieko Eriguchi, Tae Woo Kim, Tae Ik Chang, Yoshitsugu Obi, Csaba P Kovesdy, Kamyar Kalantar-Zadeh
BACKGROUND: Higher serum ferritin levels may be influenced by iron use and inflammation, and are associated with higher mortality in hemodialysis (HD) patients. We hypothesized that a major rise in serum ferritin is associated with a higher risk of mortality, irrespective of baseline serum ferritin in incident HD patients. METHODS: In a cohort of 93,979 incident HD patients between 2007 and 2011, we examined the association of change in serum ferritin from the baseline patient quarter (first 91 days from dialysis start) to the subsequent quarter with mortality...
July 14, 2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/28699885/does-helicobacter-pylori-infection-play-a-role-in-iron-deficiency-anemia-in-hemodialysis-patients
#3
Hisham El-Said, Aber Baki Attallah, Zainab A Ali-Eldin
BACKGROUND: Among the disorders that may affect patients with end-stage renal disease (ESRD), anemia is the most responsive to treatment; any reversible cause should be identified, and the most common reversible cause is iron deficiency. We investigated the relationship between Helicobacter pylori infection and iron deficiency anemia in a hemodialysis population. MATERIALS AND METHODS: This cross-sectional study included 90 adult patients with ESRD on maintenance hemodialysis...
July 12, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28674560/-management-of-chronic-hemodialysis-patients-with-anemia-case-study-conducted-in-the-department-of-nephrology-and-hemodialysis-at-the-university-hospital-point-g-in-mali
#4
Alhadji Ahmadou Tounkara, Abdoul Mahama Sériba Coulibaly, Nouhoun Coulibaly, Békaye Traoré, Mahamane Kalil Maïga
INTRODUCTION: Anemia is a frequent complication of Chronic Kidney Disease CKD commonly found in chronic haemodialysis patients. Patients management is mainly based on erythropoietin administration and iron supplementation. This study aimed to evaluate the management of chronic hemodialysis patients with anemia in the Department of Nephrology and Hemodialysis at the University Hospital Point G in Mali. METHODS: We conducted a cross-sectional study from 1 to 31 August 2016...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28662118/low-levels-of-serum-ferritin-and-moderate-transferrin-saturation-lead-to-adequate-hemoglobin-levels-in-hemodialysis-patients-retrospective-observational-study
#5
Chie Ogawa, Ken Tsuchiya, Naohisa Tomosugi, Fumiyoshi Kanda, Kunimi Maeda, Teiryo Maeda
BACKGROUND: Optimal iron levels in patients on hemodialysis are currently unknown, and a higher level than that for the healthy population is usually set for such patients considering the use of erythropoiesis-stimulating agents or the occurrence of chronic inflammation. However, excessive iron causes oxidative stress and impairment of its utilization by cells. Therefore we investigated the relationship between hemoglobin (Hb) level and iron status in hemodialysis patients to identify the optimal iron levels for patients undergoing hemodialysis...
2017: PloS One
https://www.readbyqxmd.com/read/28652444/reticulocyte-hemoglobin-content-helps-avoid-iron-overload-in-hemodialysis-patients-a-retrospective-observational-study
#6
Domenico Capone, Mauro Cataldi, Mauro Viniguerra, Teresa Mosca, Salvatore Barretta, Annalisa Ragosta, Aniello Sorrentino, Alessandra Vecchione, Luca Barretta, Giovanni Tarantino
BACKGROUND/AIM: Anemia in patients suffering from end-stage renal failure is currently treated with Erythropoiesis-Stimulating Agents (ESA). This treatment needs sufficient iron supplementation to avoid an inadequate dosage of ESA. Nowadays modern analytical instruments allow to accurately calculate the content of Hemoglobin (Hb) in reticulocytes (CHr), that can be used as a guide for prescribing patients with the appropriate amount of iron. PATIENTS AND METHODS: Patients, undergoing hemodialysis, were retrospectively selected from the database and were divided in two groups: group A received intravenous (IV) iron and subcutaneously ESA, and their dosages were adjusted on the basis of the following parameters: Hb, Mean corpuscular haemoglobin (MCH), CHr with consequent MCH/CHr ratio and reticulocyte count determined by the ADVIA 120 Hematology System of Siemens; group B patients were administered IV iron and ESA monitoring iron storage, Hb and ferritin...
July 2017: In Vivo
https://www.readbyqxmd.com/read/28648314/direct-cost-for-treating-chronic-kidney-disease-at-an-outpatient-setting-of-a-tertiary-hospital-evidence-from-a-cross-sectional-study
#7
Rajiv Ahlawat, Pramil Tiwari, Sanjay D'Cruz
BACKGROUND: Chronic kidney disease (CKD) has a high morbidity and mortality in developing countries. And this burden is also increasing rapidly in India. Unaffordability due to high cost of medication and hemodialysis remains one of the major barriers in the successful treatment of CKD. OBJECTIVES: To determine the direct cost involved in treating CKD at an outpatient department of a public tertiary care hospital. METHODS: This cross-sectional study was carried out at a public tertiary care hospital...
May 2017: Value in Health Regional Issues
https://www.readbyqxmd.com/read/28621798/the-relationship-of-serum-adipokines-with-malnutrition-inflammation-score-in-hemodialysis
#8
Elham Alipoor, Ahmad Esmaillzadeh, Mitra Mahdavi-Mazdeh, Mehdi Yaseri, Narges Sadat Zahed, Mohammad Javad Hosseinzadeh-Attar
BACKGROUND: Protein-energy wasting is a prevalent disorder in hemodialysis. Zinc-α2-glycoprotein (ZAG) and adipose triglyceride lipase (ATGL) are novel adipokines with recognized lipolytic effects and proposed role in metabolic homeostasis. This study was conducted to investigate the association of ZAG and ATGL concentrations with malnutrition inflammation score (MIS) and metabolic profile of patients with hemodialysis. MATERIALS AND METHODS: Eighty-eight patients under regular hemodialysis divided based on MIS to normal to mild wasting (NMW; n=35) or moderate wasting (MW; n=53) groups...
June 16, 2017: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28587714/real-world-effectiveness-of-sucroferric-oxyhydroxide-in-patients-on-chronic-hemodialysis-a-retrospective-analysis-of-pharmacy-data%C3%A2
#9
Daniel W Coyne, Linda H Ficociello, Vidhya Parameswaran, Ludmila Anderson, Sharanya Vemula, Norma J Ofsthun, Claudy Mullon, Franklin W Maddux, Robert J Kossmann, Stuart M Sprague
AIMS: Hyperphosphatemia has been associated with an increased risk of mortality in patients with end-stage renal disease. We sought to assess the real-world effectiveness of sucroferric oxyhydroxide (SO), an iron-based phosphate binder (PB), in control of serum phosphorus levels, and to determine the associated pill burden in hemodialysis patients. MATERIALS AND METHODS: Adult, in-center hemodialysis patients first prescribed SO through a renal pharmacy service as part of routine clinical care between April 1, 2014 and March 31, 2015 were included in the analysis...
June 7, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28570697/correction-high-fibroblast-growth-factor-23-levels-are-associated-with-decreased-ferritin-levels-and-increased-intravenous-iron-doses-in-hemodialysis-patients
#10
(no author information available yet)
[This corrects the article DOI: 10.1371/journal.pone.0176984.].
2017: PloS One
https://www.readbyqxmd.com/read/28551910/-level-and-oxidation-of-beta-2-microglobulin-in-hemodialysis-patients-treated-with-intravenous-iron-during-dialysis-with-high-flux-compared-to-low-flux-dialyzers
#11
Regina Michelis, Shifra Sela, Alexander Lanzmann, Olga Tanchilevski, Revital Shurtz-Swirski, Batya Kristal
INTRODUCTION: Serum levels of β2-microglobulin (b2M) are significantly higher in patients with end stage renal failure undergoing hemodialysis (HD) and its accumulation accelerates Dialysis Related Amyloidosis (DRA). In HD patients low-flux dialysis, intravenous (IV) iron (administered for the treatment of anemia) affects ß2M removal during dialysis. IV iron also affects the oxidation of plasma proteins, including b2M. AIMS: To examine the effect of intravenous iron therapy on ß2M levels and oxidation in HD patients treated with high-flux compared with low-flux dialyzers...
May 2017: Harefuah
https://www.readbyqxmd.com/read/28540886/effect-of-hemodialysis-on-oxidants-and-antioxidant-factors-in-chronic-renal-failure
#12
Ramin Tajbakhsh, Mostafa Qorbani, Golbarg Mehrpour, Mitra Rahimzadeh, Mohammad Mehdi Azimzadeh, Hossein Mirmiranpour
The current study was conducted to assess the effect of hemodialysis (HD) on the status of plasma oxidants and antioxidants among patients with end-stage renal disease (ESRD). These parameters can have an influence on the HD process and can also be useful for follow-up of these patients. The participants of this cross-sectional study comprised 91 patients with a mean age of 51.1 ± 8.2 years on chronic HD with kt/v between 1.2 and 1.4. The etiology of ESRD in these patients was as follows: diabetes mellitus in 39, hypertension in 35, and glomerulonephritis in 17 patients...
May 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28497091/restless-leg-syndrome-in-chronic-hemodialysis-patients-in-mashhad-hemodialysis-centers
#13
Niloufar Zadeh Saraji, Maryam Hami, Reza Boostani, Mohammad Javad Mojahedi
Introduction: Restless leg syndrome (RLS) is a sensory motor disorder. Patients with this syndrome have serious and uncontrollable desire to move their legs, which is mostly due to an uncomfortable feeling intensified when they are motionless. It may be a genetic disorder or secondary to iron deficiency, neurodegenerations, pregnancy, some drugs and severe kidney diseases. Objectives: This study was designed to find out the prevalence and its risk factors of RLS in hemodialysis patients. Patients and Methods: This multicenter cross-sectional study was done on 260 hemodialysis patients...
2017: Journal of Renal Injury Prevention
https://www.readbyqxmd.com/read/28475601/high-fibroblast-growth-factor-23-levels-are-associated-with-decreased-ferritin-levels-and-increased-intravenous-iron-doses-in-hemodialysis-patients
#14
Hirokazu Honda, Tetsuo Michihata, Kanji Shishido, Keiko Takahashi, Go Takahashi, Nozomu Hosaka, Misa Ikeda, Daisuke Sanada, Takanori Shibata
A recent study demonstrated the association between inflammation, iron metabolism and fibroblast growth factor (FGF) 23. The present clinical study aimed to assess associations between anemia, iron metabolism and FGF23 in hemodialysis (HD) patients. This prospective observational study examined a cohort of prevalent HD patients (n = 282). Blood samples were obtained before dialysis sessions to measure baseline levels of hemoglobin (Hb), transferrin saturation (TSAT), ferritin, albumin-adjusted calcium (Ca), phosphate (P), intact (i)-PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact (i)-FGF23, high sensitive (hs)-CRP, and interleukin-6...
2017: PloS One
https://www.readbyqxmd.com/read/28456484/hypersensitivity-reactions-in-patients-receiving-hemodialysis
#15
REVIEW
Lavjay Butani, Gianfranco Calogiuri
OBJECTIVE: To describe hypersensitivity reactions in patients receiving maintenance hemodialysis. DATA SOURCES: PubMed search of articles published during the past 30 years with an emphasis on publications in the past decade. STUDY SELECTIONS: Case reports and review articles describing hypersensitivity reactions in the context of hemodialysis. RESULTS: Pharmacologic agents are the most common identifiable cause of hypersensitivity reactions in patients receiving hemodialysis...
June 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28450652/concordance-between-reticulocyte-hemoglobin-equivalent-and-reticulocyte-hemoglobin-content-in-ckd-patients-undergoing-hemodialysis
#16
Riadi Wirawan, Ailinda Theodora Tedja, Fify Henrika, Aida Lydia
AIM: to evaluate the correlation and the concordance between reticulocyte hemoglobin equivalent (RET-He) and reticulocyte hemoglobin content (CHr) as well as to obtain the cut-off value of RET-He as the target of iron supplementation in chronic kidney disease (CKD) patients undergoing hemodialysis. METHODS: a cross-sectional study was performed using K3EDTA-anticoagulated peripheral blood samples collected from 106 CKD patients undergoing routine hemodialysis. The samples were then analyzed using both Sysmex XN-2000 and Siemens ADVIA 2120i for RET-He and CHr analysis...
January 2017: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/28446125/soluble-transferrin-receptor-as-a-marker-of-erythropoiesis-in-patients-undergoing-high-flux-hemodialysis
#17
Pei Yin, Jijun Li, Yan Song
Anemia is a common complication in chronic kidney disease (CKD) patients receiving hemodialysis. The effect of high-flux dialysis (HFD) on anemia remains unclear. This prospective study aimed to evaluate the effect of HFD on anemia, and the potential of soluble transferrin receptor (sTfR) as a marker of iron status and erythropoiesis in CKD patients on hemodialysis. Forty patients, who switched from conventional low-flux dialysis to HFD for 12 months, were enrolled in this study. The levels of sTfR, hemoglobin, iron, and nutritional markers, as well as the dose of recombinant human erythropoietin (rhEPO) and use of chalybeate were determined at 0, 2, 6, and 12 months after starting HFD...
April 27, 2017: Bosnian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/28418614/efficacy-and-safety-of-low-dose-heparin-in-hemodialysis
#18
Mariana Murea, Gregory B Russell, Pirouz Daeihagh, Anita M Saran, Karan Pandya, Mark Cabrera, John M Burkart, Barry I Freedman
INTRODUCTION: The dose of unfractionated heparin (UFH) administered during hemodialysis (HD) varies widely. This prospective study evaluated the safety and efficacy of UFH dose de-escalation. METHODS: Sixty-six prevalent patients on HD receiving UFH per standard-dose protocol (load dose [LD] 50-75 units/kg, maintenance dose [MD] 500-1000 units/hour) had heparin prescription converted to low-dose protocol (start LD 15 units/kg and MD 500 units/hour; dose adjusted in small increments based on assessments of extracorporeal blood circuit)...
April 18, 2017: Hemodialysis International
https://www.readbyqxmd.com/read/28416170/hepcidin-serum-levels-and-resistance-to-recombinant-human-erythropoietin-therapy-in-hemodialysis-patients
#19
Kristina Petrulienė, Edita Žiginskienė, Vytautas Kuzminskis, Irena Nedzelskienė, Inga Arūnė Bumblytė
OBJECTIVE: The aim of this study was to analyze the factors that are associated with the response to erythropoiesis-stimulating agents (ESAs) and its association with hospitalization and mortality rates; to evaluate the serum hepcidin level and its associations with iron profile, inflammatory markers, ESA responsiveness, and mortality; and to determine independent factors affecting ERI and hepcidin. MATERIALS AND METHODS: To evaluate a dose-response effect of ESAs we used the erythropoietin resistance index (ERI)...
March 31, 2017: Medicina
https://www.readbyqxmd.com/read/28381747/the-resection-of-thyroid-cancer-was-associated-with-the-resolution-of-hyporesponsiveness-to-an-erythropoiesis-stimulating-agent-in-a-hemodialysis-patient-with-aceruloplasminemia
#20
Soichiro Nagata, Naoki Ikegaya, Shuhei Ogino, Shinichi Uchida, Mikiko Itaya, Aoi Momita, Shingo Shinozaki, Masaharu Ohura, Ken Kuriki, Satoshi Kono, Hiroaki Miyajima, Akira Hishida
We herein report the case of a hemodialysis patient whose response to an erythropoiesis-stimulating agent (ESA) improved following the resection of thyroid cancer. Her hemoglobin level remained below 7 g/dL, despite the use of ESA. During the search for the causes of her hyporesponsiveness to ESA, papillary thyroid cancer and aceruloplasminemia were found. The existence of other potential causes, such as iron deficiency, infectious disease, severe hyperparathyroidism and malnutrition were ruled out. Following the resection of the thyroid cancer tumor, her hemoglobin level increased to 10...
2017: Internal Medicine
keyword
keyword
21164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"